Cargando…

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

BACKGROUND: Synaptic degeneration is an early pathogenic event in Alzheimer’s disease, associated with cognitive impairment and disease progression. Cerebrospinal fluid biomarkers reflecting synaptic integrity would be highly valuable tools to monitor synaptic degeneration directly in patients. We p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brinkmalm, Ann, Brinkmalm, Gunnar, Honer, William G, Frölich, Lutz, Hausner, Lucrezia, Minthon, Lennart, Hansson, Oskar, Wallin, Anders, Zetterberg, Henrik, Blennow, Kaj, Öhrfelt, Annika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253625/ https://www.ncbi.nlm.nih.gov/pubmed/25418885 http://dx.doi.org/10.1186/1750-1326-9-53

Ejemplares similares

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry
por: Sjödin, Simon, et al.
Publicado: (2016)

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method
por: Öhrfelt, Annika, et al.
Publicado: (2011)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
por: Lautner, Ronald, et al.
Publicado: (2017)

Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons
por: Nazir, Faisal Hayat, et al.
Publicado: (2018)

Heteromers of amyloid precursor protein in cerebrospinal fluid
por: Cuchillo-Ibañez, Inmaculada, et al.
Publicado: (2015)

Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
por: Minta, Karolina, et al.
Publicado: (2020)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
por: Minta, K., et al.
Publicado: (2020)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer’s disease patients
por: Nilsson, Jonas, et al.
Publicado: (2019)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus
por: Minta, Karolina, et al.
Publicado: (2021)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
por: Nilsson, Johanna, et al.
Publicado: (2022)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments
por: Grant, Marianne K. O., et al.
Publicado: (2019)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
por: Mattsson, Niklas, et al.
Publicado: (2016)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e0msn1l0apeqqmk0trei7gt90p